Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

4 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3

4(80.0%)

N/A

1(20.0%)

5Total

Phase 3(4)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT04335669Phase 3Active Not Recruiting

NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

Role: collaborator

NCT00798070Phase 3Active Not Recruiting

Panther: A Study Comparing Biweekly and Tailored EC-T Versus Three Weekly FEC-T in Breast Cancer Patients

Role: collaborator

NCT03655353Not ApplicableUnknown

A Study of 68Ga-ABY-025 PET for Non-invasive Quantification of HER2-expression in Advanced Breast Cancer

Role: collaborator

NCT02031042Completed

Sentinel Node Biopsy Before and/or After Neoadjuvant Chemotherapy in Breast Cancer

Role: collaborator

NCT03888677Phase 3Completed

Dose-adjusted Adjuvant FEC Compared to Standard FEC for Breast Cancer

Role: collaborator

NCT03669705Completed

No Axillary Surgery for Early Breast Cancer.

Role: collaborator

NCT03390608Completed

Prognostic and Predictive Factors for Small Breast Tumors

Role: collaborator

NCT00017095Phase 3Completed

Biomarker (p53 Gene) Analysis and Combination Chemotherapy Followed by Radiation Therapy and Surgery in Treating Women With Large Operable or Locally Advanced or Inflammatory Breast Cancer

Role: collaborator

All 8 trials loaded